Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Protagonist Therapeutics (PTGX) Shares Outstanding (Weighted Average) (2017 - 2025)

Protagonist Therapeutics' Shares Outstanding (Weighted Average) history spans 9 years, with the latest figure at $63.6 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) rose 3.26% year-over-year to $63.6 million; the TTM value through Dec 2025 reached $63.6 million, up 3.26%, while the annual FY2025 figure was $63.6 million, 3.26% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $63.6 million at Protagonist Therapeutics, roughly flat from $63.8 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $63.8 million in Q3 2025 and bottomed at $44.2 million in Q1 2021.
  • The 5-year median for Shares Outstanding (Weighted Average) is $56.8 million (2023), against an average of $55.2 million.
  • The largest annual shift saw Shares Outstanding (Weighted Average) surged 59.63% in 2021 before it grew 2.05% in 2022.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $46.3 million in 2021, then grew by 5.72% to $49.0 million in 2022, then grew by 15.91% to $56.8 million in 2023, then increased by 8.46% to $61.6 million in 2024, then increased by 3.26% to $63.6 million in 2025.
  • Per Business Quant, the three most recent readings for PTGX's Shares Outstanding (Weighted Average) are $63.6 million (Q4 2025), $63.8 million (Q3 2025), and $63.5 million (Q2 2025).